PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1988 May; 81(5): 274–276.
PMCID: PMC1291586

Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.

Abstract

The efficacy of gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia was evaluated in 26 individuals over a mean period of 16 months. In the untreated state both disorders are associated with a high frequency of coronary heart disease. In the former, gemfibrozil with a bile acid sequestrant reduced plasma cholesterol by 32%, an incremental decrease of 17% compared with sequestrant therapy alone. In type III, plasma cholesterol was reduced by 40% and plasma triglyceride by 70%, while high-density lipoprotein cholesterol increased by 45%. In none of the patients studied did clinical or biochemical side effects occur.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (525K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Samuel P. Effects of gemfibrozil on serum lipids. Am J Med. 1983 May 23;74(5A):23–27. [PubMed]
  • Nye ER, Sutherland WH, Temple W a. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. N Z Med J. 1980 Nov 12;92(671):345–349. [PubMed]
  • Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. [PubMed]
  • Brewer HB, Jr, Zech LA, Gregg RE, Schwartz D, Schaefer EJ. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med. 1983 May;98(5 Pt 1):623–640. [PubMed]
  • Choudhury S, Jackson P, Katan MB, Marenah CB, Cortese C, Miller NE, Lewis B. A multifactorial diet in the management of hyperlipidaemia. Atherosclerosis. 1984 Jan;50(1):93–103. [PubMed]
  • Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 1978 Jan;19(1):65–76. [PubMed]
  • Hoogwerf BJ, Bantle JP, Kuba K, Frantz ID, Jr, Hunninghake DB. Treatment of type III hyperlipoproteinemia with four different treatment regimens. Atherosclerosis. 1984 May-Jun;51(2-3):251–259. [PubMed]
  • Howard AN, Hyams DE. Combined use of clofibrate and cholestyramine or DEAE sephadex in hypercholesterolaemia. Br Med J. 1971 Jul 3;3(5765):25–27. [PMC free article] [PubMed]
  • Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986 Oct 25;2(8513):933–936. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press